Recent events
Recent events tied to this brand in public sources.
Back to profile56 entries · Page 3 of 3
2021
Cipla signs baricitinib licensing agreement with Eli Lilly
Cipla announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and commercialization of baricitinib for COVID-19 in India.
2021
Rigel and Lilly close global license agreement and collaboration
Rigel Pharmaceuticals announced the closing of its global exclusive license agreement and strategic collaboration with Eli Lilly and Company. The agreement is effective March 27, 2021; Rigel received the $125 million upfront payment, and the collaboration covers co-development and commercialization of R552 and Lilly-led clinical development of penetrating RIPK1 inhibitors for CNS diseases.
2021
Elsevier releases updated DDIRC 2.0 in PharmaPendium
Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.
2021
Lilly appoints Anat Ashkenazi as CFO successor
Eli Lilly and Co. appointed Anat Ashkenazi to replace Josh Smiley as chief financial officer.
2021
Lilly CFO Josh Smiley leaves the company
Eli Lilly and Co. said CFO Josh Smiley was leaving the company after an investigation found inappropriate personal communications with a Lilly employee.
2021
Lilly announces licensing agreement for AK1780
Eli Lilly and Asahi Kasei Pharma announced a licensing agreement giving Lilly exclusive rights to AK1780. Lilly will be responsible for its global development and regulatory activities, and the transaction remains subject to customary closing conditions.
2020
Lilly and the China Sexology Association launch Night Questions 365
Lilly and the China Sexology Association launched Night Questions 365, a male-health educational publication, at an event in Beijing.
2020
FDA approves Lilly’s Lyumjev insulin
Eli Lilly said it received U.S. Food and Drug Administration approval for Lyumjev, its new rapid-acting insulin.
2020
FDA approves Lilly's Lyumjev insulin
The U.S. Food and Drug Administration approved Eli Lilly and Company's Lyumjev rapid-acting insulin for improving glycemic control in adults with type 1 and type 2 diabetes.
2020
Lilly pledges funding and volunteer hours to address racial injustice
Eli Lilly and Co. and the Lilly Foundation announced a five-year pledge of $25 million and 25,000 employee volunteer service hours to address racial injustice and its effects on communities of color.
2020
Lilly and media partners announce Indy Day of Solidarity virtual event
Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV announced the Indy Day of Solidarity virtual event, scheduled for June 13, 2020, to acknowledge racial injustice and encourage a call to action for lasting change.
2020
Lilly and partners collaborate on Indy Day of Solidarity
Eli Lilly and Company, Radio One, Indianapolis Recorder and WISH-TV invited people and organizations to participate in the virtual Indy Day of Solidarity, planned for Saturday, June 13, to address racial injustice and encourage action for lasting change.
2020
Eli Lilly reports fourth-quarter and full-year 2019 results
Eli Lilly announced its fourth-quarter and full-year 2019 financial results, reporting full-year revenue of $22.319 billion and fourth-quarter revenue of $6.114 billion.
2020
Eli Lilly updates 2020 earnings guidance
Eli Lilly updated its 2020 reported EPS guidance to $6.18–$6.28 as a result of its pending Dermira acquisition and reaffirmed its non-GAAP EPS guidance at $6.70–$6.80.
2019
Lilly launches insulin cost-saving awareness campaign
Eli Lilly launched an awareness campaign promoting cost-saving options for people who need help affording Lilly insulin. The campaign included an open letter published in newspapers and a digital advertising campaign planned to run later that month through March.
2015
Eli Lilly to exclusively sponsor CNN Films Presents broadcasts
CNN announced that CNN Films Presents broadcasts of “Glen Campbell... I'll Be Me,” planned for June and November 2015, would have exclusive sponsorship from Eli Lilly and Company.